How should peptic ulcer disease be managed in a patient who tests negative for Helicobacter pylori?

Management of H. pylori-Negative Peptic Ulcer Disease

In patients with peptic ulcer disease who test negative for H. pylori, the primary management is proton pump inhibitor (PPI) therapy—or preferably vonoprazan—while systematically investigating for NSAIDs/aspirin use (the most common cause), ensuring accurate H. pylori testing wasn't compromised, and excluding rare secondary causes before diagnosing idiopathic ulcers.

Immediate Diagnostic Considerations

Before accepting a negative H. pylori result, you must verify test accuracy. False-negative H. pylori tests occur in up to 25% of cases labeled as "H. pylori-negative" 1, 2. Specifically:

• Recent medication exposure causes 20% of false negatives: antibiotics, bismuth, or PPIs taken within 2-4 weeks before testing 2
• True false-negative tests account for 5% 2
• Retesting with a different modality (urea breath test or stool antigen) is essential if clinical suspicion remains high

Identify the Underlying Cause

NSAIDs/Aspirin (50-60% of true H. pylori-negative ulcers)

NSAID use is by far the most common cause of H. pylori-negative peptic ulcers 1, 2, 3. Critical points:

• Surreptitious NSAID use accounts for up to 60% of "unexplained" ulcers 1
• Question patients specifically about over-the-counter ibuprofen, naproxen, aspirin (including low-dose for cardiovascular protection)
• Ask about topical NSAIDs, which patients often don't consider "real" medications
• The combination of H. pylori and NSAIDs increases bleeding risk more than sixfold 4

Rare Secondary Causes (<5% of cases)

Exclude these systematically 1, 2, 3:

• Zollinger-Ellison syndrome: Check fasting gastrin level if ulcers are multiple, refractory, or in unusual locations
• Crohn's disease: Consider if there are other GI symptoms or extraintestinal manifestations
• Other infections: Helicobacter heilmannii (rare)
• Systemic diseases: amyloidosis, eosinophilic gastroenteritis

Idiopathic Ulcers (5-15% of cases)

After excluding all identifiable causes, a small proportion remain truly idiopathic 1, 2. These patients often have:

• Acid hypersecretion as a pathogenic factor 2, 3
• More resistance to standard therapy 1
• Higher complication rates 1
• Approximately 50% of H. pylori-negative duodenal ulcers have no apparent explanation 3

Treatment Algorithm

First-Line Pharmacologic Management

The 2026 Japanese guidelines now recommend vonoprazan as first-line treatment over traditional PPIs for peptic ulcers 5. This represents the most current high-quality guidance:

• Vonoprazan has superior acid-inhibitory characteristics compared to PPIs 5
• Standard PPI therapy remains effective if vonoprazan is unavailable 6, 5
• Treatment duration: typically 4-8 weeks depending on ulcer size and location

NSAID-Related Ulcer Management

If NSAIDs are the identified cause 6, 5:

1. Discontinue the NSAID if possible
2. If NSAID continuation is necessary:
   • Coadminister PPI or vonoprazan for prevention 6, 4
   • Consider switching to celecoxib (less gastric mucosal effect) 4
   • Misoprostol is an alternative protective agent 7

Management of Idiopathic Ulcers

Idiopathic ulcers are more resistant to standard therapy and require long-term maintenance 1:

• Higher-dose or prolonged acid suppression may be necessary
• Consider maintenance PPI/vonoprazan therapy for relapse prevention
• Monitor closely for complications given higher risk profile

Critical Pitfalls to Avoid

1. Accepting initial negative H. pylori testing without verifying medication history: Always confirm no recent PPI, antibiotic, or bismuth use before testing
2. Missing surreptitious NSAID use: Explicitly ask about all over-the-counter medications, topical preparations, and aspirin
3. Failing to consider rare causes in refractory cases: Check gastrin levels if ulcers are atypical or treatment-resistant
4. Undertreating idiopathic ulcers: These require more aggressive and prolonged therapy than H. pylori-positive ulcers 1, 3

Long-term Considerations

H. pylori-negative ulcers, particularly idiopathic ones, have higher recurrence rates and may require indefinite maintenance acid suppression 1. The increasing prevalence of idiopathic ulcers in recent years reflects declining H. pylori prevalence in developed countries 5, making this an increasingly relevant clinical scenario.

For patients requiring long-term PPI therapy, monitor for potential risks including fractures, micronutrient deficiencies (B12, magnesium, calcium), and drug interactions 4.